SYK · Earnings call · 2026Q3T · Full report

Regulatory Approval Milestones

STRYKER CORP · 2026-10-29 · Importance 34 · Surprise 42

Stryker’s Peripheral Vascular joint venture in China generated one-time Q3 revenue after reaching a regulatory approval milestone in September. Management said it expects FDA approval of AVS’s IVL product toward the end of 2026 and is preparing the commercial launch, with commercialization expected to begin in 2027. Management also cited the regulated nature of medical technology as a factor that can lengthen the time for innovations such as AI to affect the market, and noted that the company has three FDA-approved AI products.

Key facts

• Stryker expected FDA approval for the AVS product toward the end of 2026 and said it would support its Peripheral Vascular business.
• Stryker's Q3 2026 included one-time revenue from its Peripheral Vascular joint venture in China after a regulatory approval milestone was achieved in September.